Should a patient who was taking 28 units of U‑100 insulin continue to take 28 units after switching to insulin glargine U‑200 (Tresiba)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, she should continue taking 28 units when switching from U-100 insulin to Tresiba U-200.

The dose in units remains the same when switching between U-100 and U-200 formulations of the same insulin—only the concentration changes, not the actual dose administered. This is explicitly confirmed by the FDA label for Tresiba, which states that "Total and maximum insulin degludec exposure at steady state are comparable between TRESIBA U-100 and TRESIBA U-200 when each is administered at the same units/kg dose" 1.

Key Dosing Principle

The U-200 formulation is simply twice as concentrated as U-100, meaning:

  • 28 units of U-100 = 28 units of U-200
  • The volume injected will be half (0.14 mL instead of 0.28 mL), but the actual insulin dose remains identical
  • The pen device automatically accounts for the concentration difference

Critical Safety Considerations

Common pitfall to avoid: Do not confuse concentration with dose. The "200" in U-200 refers to concentration (200 units per mL), not a doubling of the dose. Patients and providers sometimes mistakenly think they need to halve the dose when switching to U-200, which would result in severe underdosing.

Why U-200 exists: The concentrated formulation allows delivery of higher insulin doses in smaller injection volumes, which can improve absorption and patient comfort—particularly relevant for insulin-resistant patients requiring large doses 2. However, the actual unit dose prescribed remains unchanged during conversion.

Monitoring After Switch

While the initial dose stays at 28 units, monitor glucose closely during the first 3-4 days as Tresiba reaches steady state 1. The ultra-long duration of action (>42 hours) means:

  • Steady state is achieved after 3-4 days of daily dosing
  • Dose adjustments should be made cautiously with at least 3 days between changes
  • The prolonged action provides more stable glucose control but requires patience during titration

Real-world evidence confirms that when patients switch from other basal insulins to ultra-long-acting formulations like Tresiba U-200, they often end up requiring slightly lower total daily doses over time (approximately 13 units less at 6 months) while achieving better HbA1c control 3. However, start with the same 28 units and titrate based on glucose response, not based on the concentration change.

Related Questions

Can Toujeo SoloSTAR (insulin glargine U‑300) be substituted for insulin glargine (U‑100)?
Should I decrease my insulin glargine (Lantus) dose, currently 22 units, given a blood glucose of 219 mg/dL at 2 am and 152 mg/dL at 7 am?
How should the insulin regimen be adjusted for a patient with a recent A1C of 10% who is currently on sliding‑scale insulin and insulin glargine (100 U/mL)?
For a female patient weighing 43 kg with a hemoglobin A1c of 13 % and normal renal function who is started on insulin glargine (100 units/mL), how many milliliters of insulin should be administered, how often should it be given each day, and which oral antidiabetic agents should be added?
Does Basaglar (insulin glargine) come in a vial?
Is starting atomoxetine 40 mg daily appropriate for an adult patient with attention‑deficit/hyperactivity disorder who weighs at least 70 kg and has no contraindications?
Is testosterone therapy appropriate for a 72-year-old woman with estrogen-sensitive breast cancer to improve libido and muscle mass?
What is the differential diagnosis for an 8‑year‑old with brief daily episodes over three months of chest pain, headache, palpitations, blurred vision, left upper‑limb numbness, and left eye pain?
What is the appropriate management for stress‑induced asthma?
What additional management options are recommended for a patient with posterior tibial neuropathy (positive too many toes sign) and posterior tibial tendinopathy who is already using arch support?
I am taking atomoxetine 40 mg daily and still have difficulty focusing; should I increase the dose or consider alternative treatments?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.